Friedrich von Bohlen
Chair

von Bohlen

Friedrich von Bohlen und Halbach is managing partner and co-founder of dievini Hopp BioTech Holding GmbH & Co. KG., the company managing the life science activities and investments of Dietmar Hopp, co-founder of SAP, and his family. Friedrich von Bohlen holds a diploma in biochemistry from the University of Zurich and a PhD in neurobiology from the Swiss Federal Institute of Technology (ETH) in Zurich. He held various positions at Fresenius AG, FAG Kugelfischer KGaA, and WASAG Chemie AG. In 1997 he founded LION bioscience AG whose CEO he was for seven years. He is chairman of the Board of Apogenix AG and Novaliq GmbH, as well as board member of CureVac AG, immatics biotechnologies GmbH, Heidelberg Pharma AG, and Chair of the Evaluation Board of the Wyss Zurich. Friedrich is also co-founder and managing director of Molecular Health GmbH.


Wolfram Burgard

Burgard

Wolfram Burgard is a Professor of Robotics and Artificial Intelligence at the University of Technology Nuremberg. Before this, he was a Professor for Autonomous Intelligent Systems at the University of Freiburg and also Vice President for Automated Driving Technology at the Toyota Research. His areas of interest lie in artificial intelligence and mobile robots. His research mainly focuses on the development of robust and adaptive techniques for robot state estimation and control. Over the past years, his group has developed a series of innovative probabilistic and machine learning techniques for robot navigation and perception. Wolfram Burgard has coauthored over 400 publications in robotics and artificial intelligence. He is a Fellow of the European European Association for Artificial Intelligence (EurAI), the Association for the Advancement of Artificial Intelligence (AAAI), and the Institute of Electrical and Electronics Engineers (IEEE). In 2009, he received the Gottfried Wilhelm Leibniz Prize, the most prestigious German research award. In 2010, he earned an Advanced Grant from the European Research Council. He is a member of the Heidelberg Academy of Science and the National Academy of Science Leopoldina. In 2022, he received the Technical Field Award of the IEEE Robotics and Automation Society.


Gery Colombo

Colombo

Gery Colombo graduated in electrical engineering and obtained a PhD in the field of biomedical engineering both at the ETH of Zurich. He worked as the head of the research lab in the spinal cord injury center of the university hospital Balgrist in Zurich from 1993 to 2002. In 2000 Gery Colombo co-founded the spin-off company Hocoma AG which he managed as the CEO from 2002 to 2020. Hocoma was a pioneer in rehabilitation robotics and became the global leader in the field of rehabilitation technology. IISART, the International Industry Society in Advanced Rehabilitation Technology was also initiated by Gery Colombo and he was the president for the first 8 years. Today he is active in boards of directors and advisory boards of different companies and societies in the field of technology and healthcare. He received several awards for his innovations and for management.


Dominik Escher

Escher

Dominik Escher is a co-founder and Executive Chairman of CDR-Life AG and a founding partner of Pureos Bioventures. He is also president of the Swiss Biotech Association. Previously, he was a founder and CEO of ESBATech AG, which was acquired in 2009 by Alcon (Novartis) for USD 589 million. As a biotech entrepreneur, he raised USD 89 million for ESBATech to develop novel antibody fragments from discovery to maturity, delivering multiple clinically successful products (e.g. Brolucizumab, FDA approval for wet AMD in October 2019). Dominik obtained his Ph.D. in Molecular Biology from the University of Zurich and also holds a Masters Degree in Education with specialization in Management and Organization from the ETH of Zurich.


Robert Frigg

Frigg

Robert Frigg has been an active medical device developer and innovator for over 40 years. He started his career in 1978 at the Lab for Experimental Surgery in Davos and became Chief Technology Officer (CTO) of Synthes Inc., a global leader in orthopedics. During his time as a developer in the industry, he supported and advised many research projects at universities and hospitals for which he has received multiple awards. Since 2013, Robert Frigg manages the MedTech company 41medical and since 2019 chairs the company as co-owner. He and his team support start-up projects and innovation at several universities and institutions. This includes the Balgrist Campus and Balgrist Beteiligungs AG in Zurich, the ieLab at ETH Zürich, the Empa, Campus SLB of the Lindenhof group, the Institute for Clinical Innovation at the University of Salzburg Medical School, Biomedical Innovation, the Queensland University of Technology in Brisbane, the Berlin Institute of Health (Charité) and the Innovation Translation Center of the AO Foundation.


Hans Christoph Tanner

Tanner

Chris Tanner is a member of the board of CureVac NV(NASDAQ:CVAC), DKSH AG (SIX:DKSH), Paion (ETR:PA8), Joimax GmbH, and Qvanteq AG.
Chris Tanner was at UBS from 1977 to 1998 initially in the Corporate Banking Department and, from 1991-1998 headed the Capital Markets and Corporate Finance Department in Zurich. He was a co-founder of the newspaper group 20 Minutes in 1999, a co-investor in Plus Endoprothetik AG in 2001, and after raising the financing for Cosmo Pharmaceuticals in 2005, joined it in 2006 and brought it public in 2007. In 2015, he led the spin-off of Cassiopea SpA from Cosmo Pharmaceuticals and was its CFO until his retirement at end of 2020. Chris Tanner has a diploma (Lic Oec) in macroeconomics from the University of St. Gallen and a PhD on steering migration in developing countries from the University of St. Gallen.


Brigitte von Rechenberg

von Rechenberg

Brigitte von Rechenberg is Professor of experimental veterinary surgery at the Vetsuisse Faculty of Zurich. She is the founder and head of the Musculoskeletal Research Unit (MSRU) as well as the head of the Steering Committee of the official Competence Center of Applied Biotechnology and Molecular Medicine (CABMM). Her own research focuses on bone and cartilage remodeling and regeneration. Trained as a Board Certified small animal surgeon (ECVS) she is specialized in experimental surgery and preclinical animal studies and her laboratory is the only officially accredited GLP facility for large animal and small laboratory rodents studies at a University in Europe. From 2014 to 2018 Brigitte von Rechenberg was the first female Dean of the Vetsuisse Faculty Zurich.

Former Board Members: Felix Mayer, Ian Roberts